当前位置： SCI文献检索 > Orphanet Journal of Rare Diseases期刊下所有文献 > The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.

Abstract：

BACKGROUND:Orphan medicinal products (OMPs) are intended for the diagnosis, prevention, management or treatment of rare diseases (RDs). Each RD affects only a small fraction of the population, and therefore, historically, industry hesitated to undertake relevant research and development (R&D). In response, the governments of many countries came up with orphan drug policies and RD policies which were hugely successful in incentivizing companies to do so. In India, in the absence of any such policy until recently, there are very few organizations involved in RD R&D. OBJECTIVES:We wished to understand (i) the OMP Organizations' (OMPOs') areas of work and the nature of their work, (ii) their goals, (iii) the challenges they faced and how they were overcoming them, (iv) their achievements, and (v) their recommendations to the government to help their R&D, their success as commercial entities (where applicable), and patients' access to their products or services. RESULTS:Ten of the 14 OMPOs are companies, whereas four are not-for-profit organizations. Almost all of the OMPOs are heavily into R&D. Six have already made their products or services available to patients. Four plan to out-license their products after the pre-clinical phase or phase 1 trials, eight plan to cater to patients directly and two of the OMPOs have been established only recently and thus do not yet have any product or service to offer patients. Nine OMPOs import about 90% of the components in the production process, which comprises either capital or recurrent expenditure. For most, locally manufactured alternatives are not available or are of inadequate quality. Most of the OMPOs have had productive collaborations with local or foreign academics or hospitals for R&D, animal efficacy studies, clinical trials or providing services to patients. The main challenges for the OMPOs are the lack of adequate funding, supportive government policies, and a conducive ecosystem. CONCLUSIONS:These OMPOs are pioneers in their respective fields in India, and despite the challenges, have achieved new levels of innovation. With suitable government policies, they could scale up and provide relevant products and services to the large number of RD patients in the country whose medical needs are largely unmet.

journal_name

Orphanet J Rare Dis

journal_title

Orphanet journal of rare diseases

authors

Choudhury MC,Saberwal G

doi

10.1186/s13023-019-1224-0

subject

Has Abstract

pub_date

2019-11-04 00:00:00

pages

241

issue

issn

1750-1172

pii

10.1186/s13023-019-1224-0

journal_volume

pub_type

杂志文章

在线工具

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.